Napredna pretraga

Pregled bibliografske jedinice broj: 913175

Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.


Hauser, Goran; Blažević, Ivana; Salkić, Nermin; Poropat, Goran; Giljača, Vanja; Bulić, Zlatko; Štimac, Davor
Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial. // Surgical endoscopy, 31 (2017), 602-610 doi:10.1007/s00464-016-5004-9 (podatak o recenziji nije dostupan, članak, znanstveni)


Naslov
Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.

Autori
Hauser, Goran ; Blažević, Ivana ; Salkić, Nermin ; Poropat, Goran ; Giljača, Vanja ; Bulić, Zlatko ; Štimac, Davor

Izvornik
Surgical endoscopy (0930-2794) 31 (2017); 602-610

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
ERCP, Post ERCP pancreatitis

Sažetak
Background and Aims: We aimed to compare the efficacy of prophylactic, parenterally administered ceftazidime and rectally applied diclofenac sodium for the prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). Methods: We prospectively enrolled patients who underwent ERCP. In a doubleblinded randomized controlled trial, patients received a suppository containing diclofenac sodium rectally (100 mg) and placebo intravenously (group A) or ceftazidime intravenously (1 g) and placebo rectally (group B) immediately before the procedure. The serum and urine amylase levels were recorded and the patients were clinically evaluated after ERCP. Results: Of the 272 patients enrolled (group A: 129 ; group B: 143), 32 developed pancreatitis (group A: 11 [8.5%] ; group B: 21 [14.7%] ; P = 0.17 ; relative risk = 1.72 ; 95% confidence interval [CI] = 0.86-3.43). The severity of the pancreatitis or complications did not significantly differ between the groups. A serum amylase level of ≥ 560 U/L and urine amylase level of ≥ 1150 U/L indicated a positive likelihood ratio for post-ERCP pancreatitis of ≥ 10. Moreover, the threshold visual analog scale score of ≤ 5 for abdominal pain after ERCP had excellent diagnostic potential for predicting the presence or absence of post-ERCP pancreatitis. Conclusions: The PEP incidence did not differ between the ceftazidime and diclofenac sodium groups. In patients with nonsteroidal anti-inflammatory drug contraindications, antibiotics can be considered a safe alternative to diclofenac sodium for PEP prevention. Moreover, the visual analog scale for abdominal pain has excellent diagnostic value for predicting PEP. Clinical trials.gov number, NCT 01784445.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka,
Fakultet zdravstvenih studija u Rijeci

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati